Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024
CAMBRIDGE,Mass.,ROTTERDAM,Netherlands and SUZHOU,China,Sept. 14,2024--Harbour BioMed (the "Company"; HKEX: 02142),a global biopharmaceutical company committed to the discovery,development,a